Conjugates between proteins and small molecules enable access to a vast chemical space that is not achievable with either type of molecule alone; however, the paucity of specific reactions capable of functionalizing proteins and natural products presents a formidable challenge for preparing conjugates. Here we report a strategy for conjugating electron-rich (hetero)arenes to polypeptides and proteins. Our bioconjugation technique exploits the electrophilic reactivity of an oxidized selenocysteine residue in polypeptides and proteins, and the electron-rich character of certain small molecules to provide bioconjugates in excellent yields under mild conditions. This conjugation chemistry enabled the synthesis of peptide-vancomycin conjugates without the prefunctionalization of vancomycin. These conjugates have an enhanced in vitro potency for resistant Gram-positive and Gramnegative pathogens. Additionally, we show that a 6 kDa affibody protein and a 150 kDa immunoglobulin-G antibody could be modified without diminishing bioactivity.
S
ynthesizing covalent conjugates of a peptide or protein and a complex small molecule is often challenging with the available chemical tools. However, such conjugates may have clinical value as they can direct small-molecule toxins to certain tissues, widen therapeutic windows and tune pharmacokinetic and pharmacodynamic properties often beyond the capabilities of each component alone 1 . For example, a conjugate of the highly cytotoxic agent emtansine (DM1) with trastuzumab, a HER2 selective antibody, is used clinically to treat late-stage breast cancer 2 . Early antibody-drug conjugates (ADCs) were prepared in a heterogeneous fashion, usually by linking the exposed lysine residues on the antibody with N-hydroxysuccinimide ester derivatives of the small-molecule payload [3] [4] [5] . Alternatively, cysteine conjugation is facilitated by the reduction of the four interchain disulfide bonds, followed by reaction with a maleimide-linked payload [6] [7] [8] . Given the varying stability and efficacy of heterogeneous ADCs, the ADC field has prioritized the development of new methods to create homogeneous ADCs 9 . Current methods to manufacture homogeneous ADCs include leveraging the reactivity of cysteine and lysine, incorporating unnatural amino acids into the antibody and utilizing conserved glycans on the antibody surface 9 . Many of these strategies require modification of both the antibody and the small molecule to enable homogeneous linkage, which is frequently laborious.
The direct and chemoselective conjugation of complex small molecules to peptides or proteins is a formidable task due to the presence of multiple nucleophilic and electrophilic functional groups. To achieve this conjugation with a high selectivity, the reactivity of the small molecule must be complementary with the reactivity of the coupling functional group in the biopolymer. In particular, a technique for the replacement of an aromatic C-H bond of a small molecule with a biopolymer would be an especially straightforward and appealing means to couple two complex fragments. There are several examples of using both metal-free and copper-catalysed reactions to connect aryl thiols to arenes [10] [11] [12] . Additionally, C-S and C-Se bond formation with indoles using iron-catalysed chemistry with diaryl disulfides and diaryl selenides has been demonstrated 13 . Unfortunately, these techniques often require bioincompatible solvents, such as dimethylformamide and are performed between two small molecules. However, these types of reactions suggest that an electrophilic disulfide, diselenide or mixed Se-S bond in a biopolymer may be able to be used for a direct aromatic C-H bond replacement if the conditions are milder.
We recently reported the selective formation of C-Se bonds in unprotected peptides containing an oxidized, electrophilic selenocysteine residue (Sec) 14 . This approach exploited an electrophilic Se-S bond in combination with a copper reagent and a boronic acid to selectively arylate the selenium of selenocysteine. Despite the elaborate scope and mild conditions, this method required the use of a boronic acid functional group to facilitate the C-Se bond formation. The need for the boronic acid hampers the overall efficiency for conjugating complex small molecules to biopolymers because additional synthetic steps are needed to install the prerequisite boronic acid 15 . Having demonstrated that we can access electrophilic selenocysteine under mild biocompatible conditions, we questioned whether our electrophilic selenium reagent in combination with electron-donating arenes could be used to achieve the direct conjugation of unmodified small molecules to peptides and proteins (Fig. 1) . If effective, this would be a general route for the conjugation of natural products and pharmaceuticals with electronrich units to peptides and proteins. Here we report an approach to creating peptide-and protein-small molecule conjugates by matching the inherent reactivity of a small molecule with an oxidized Sec. This strategy exploits the unique nature of electrophilic Sec in combination with the electron-rich nature of arene-containing small molecules to provide the respective conjugate (Fig. 1) .
results and discussion
We began our investigations with the conjugation of vancomycin to antimicrobial peptides that containing an oxidized Sec. Vancomycin provided a good candidate for the small-molecule component, as the embedded electron-rich resorcinol ring of vancomycin serves as a site for conjugation. Additionally, vancomycin is a potent antibiotic often used as the first-line treatment for methicillin-resistant Staphylococcus aureus 16 . We hypothesized that the conjugation to antimicrobial peptides may be beneficial as vancomycin is unable to penetrate the outer membrane of Gram-negative bacteria 17 . Also, compared with larger proteins, small antimicrobial peptides have a lower complexity starting point for the development of our chemistry. On incorporation of an oxidized Sec into various antimicrobial peptides, the conjugation reaction described herein provides a rapid and convenient single-step approach to prepare a small library of antibacterial peptide-vancomycin conjugates in multimilligram quantities (Fig. 2a) .
The reactions were run in aqueous pH 8 media at 37 °C for 3-5 hours. The corresponding conjugates were formed in a 40-90% yield based on liquid chromatography-mass spectrometry (LC-MS) of the unpurified reaction mixture. After purification by reverse-phase high-performance liquid chromatography (RP-HPLC), the corresponding vancomycin-antimicrobial conjugates were isolated in milligram quantities (Supplementary Section 13). To ascertain the regioselectivity for the conjugation of vancomycin to these antibacterial peptides, we prepared a vancomycin-peptide complex that lacked any aromatic residues (13i, Fig.  2b ) and fully characterized it using detailed 2D NMR experiments (Supplementary Section 10). The observed rotational nuclear Overhauser effect spectroscopy (ROESY) and heteronuclear multiple bond correlation (HMBC) indicated that selenation had occurred on 'carbon d' between the two hydroxyl groups of the resorcinol ring of vancomycin (Fig. 2b) .
We treated several strains of Gram-positive and Gram-negative bacteria with a small library of antibacterial peptide-vancomycin conjugates generated through our conjugation chemistry. This library served two key purposes: (1) to determine if the antibacterial peptide-vancomycin conjugates could overcome resistance mechanisms in known vancomycin-resistant Gram-positive bacterial strains and (2) to see if our conjugates are effective against Gram-negative bacteria, as the antibacterial peptide may improve the delivery of vancomycin across the outer membrane. From the library of peptide-vancomycin compounds, we discovered two conjugates that were more active than either the parent peptide or vancomycin.
With regards to treating the Gram-positive strain Enterococcus faecalis VRE (VanB), the K4-S4(1-13a) dermaseptin-vancomycin conjugate 18 (19v) was more potent than vancomycin alone (van), any of the parent peptides tested (19p and 19ep) and the unconjugated mixtures of vancomycin with the parent peptides (van+ 19p and van+ 19ep). On a molar basis, 19v was over five times more potent than vancomycin and 20 times more potent than the parent peptide ( Fig. 2c ). For Gram-negative bacteria, the kinocidin congener peptide RP-1-vancomycin conjugate (23v) 19 was active against the Gram-negative bacterium Acinetobacter baumannii with a minimum inhibitory concentration (MIC) of 16 μ g ml -1 (4 μ M, Fig. 2d ). This result is surprising as, separately, vancomycin and the parent peptide (23p) are both ineffective for treating A. baumannii (Fig.  2d) . Effective therapies for A. baumannii would be highly valuable, as this organism can become multidrug resistant easily and is a source of nosocomial (hospital-acquired) infection, especially in immunocompromised patients [20] [21] [22] . Future work will be necessary to determine the mechanism of these conjugates and whether or not the vancomycin component is functionally consequential. However, these initial studies validate the chemistry and suggest that it may enable the discovery of antibiotic conjugates with efficacy against resistant pathogens.
One other consideration for the in vivo application of this chemistry is the metabolism of the conjugates. Although 23v shows no toxicity against eukaryotic cells in vitro (Supplementary Section 20), selenium metabolism in vivo is more complicated and toxicity could be difficult to predict. For example, one described pathway of metabolism for selenocysteine Se conjugates in mice is β elimination in the kidney to generate selenol metabolites 23, 24 . Selenols can be strong nucleophiles and strong reducing agents, which are advantageous properties that enable the scavenging of toxic electrophilic metabolites and provide protection against radicals. However, selenol species can also auto-oxidize into diselenides in the presence of molecular oxygen to produce superoxide anion radicals and hydrogen peroxide as by-products. Reduction back to the selenol by intracellular glutathione and subsequent oxidation can lead to a self-propagating cascade that results in toxic levels of reactive oxygen species 25 . As the properties of the selenol species depend on the substituent on selenocysteine, the metabolites of selenocysteine-conjugated vancomycinantimicrobial peptide conjugates could have beneficial or toxic effects. Therefore, in vivo metabolism will be the subject of future investigation. The conjugation reaction proceeded smoothly for the attachment of 1-3 kDa peptides to vancomycin, so we aimed to expand the scope of our chemistry by attaching small proteins onto vancomycin. We chemically synthesized a Sec-containing variant of the trihelical affibody protein (25) frequently used in protein engineering and designed to target proteins such as the HER2 receptor 26 . Conjugating small molecule drugs to specific affibody variants enabled localization of these small molecules to specific targets 27 . The p-methoxybenzyl-protected selenocysteine affibody derivative (25) folded into an α -helical structure that had a circular dichroism (CD) spectrum nearly identical to the wild-type (WT) affibody (Fig. 3c) , which indicates that the addition of a glycine-selenocysteine dipeptide at the N terminus did not significantly change the affibody structure. The activated Se-S bond was installed in one step and the resulting crude material was directly conjugated to vancomycin to afford the corresponding conjugate (27) in a 23% isolated yield after purification by RP-HPLC (Fig. 3a,b) . The folded affibody-vancomycin conjugate 27 also retained the α -helical structure, as indicated by its characteristic CD spectrum (Fig. 3c) . Furthermore, the conjugate 27 readily bound to trastuzumab with a dissociation constant (K D ) of 2.6 ± 0.2 nM, a value comparable to that of the WT affibody (K D = 2.0 ± 0.2 nM, Supplementary Section 25) (Fig. 3d) . Collectively, these results demonstrate that there was minimal perturbation of the affibody structure and function after conjugation to vancomycin.
Another potential application of our chemistry is to the generation of homogeneous ADCs. As a first step, we prepared functional antibody conjugates using sortase-mediated ligation of a selenocysteine-containing peptide (Fig. 4) 
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. We first conjugated unmodified genistein 29 onto a polyglycine sortase A substrate peptide 28 to provide peptide conjugate 28a in a 72% yield after RP-HPLC purification (Fig. 4a) . We then reacted the loaded polyglycine peptide 28a with a HER2-targeted immunoglobulin-G (150 kDa) that bore a sortase A LPSTG motif on the C terminus of each heavy chain. After deglycosylation with PNGase F, analysis by LC-MS of the final trastuzumab-genistein conjugate (30) showed a complete and specific drug conjugation on the heavy chains of the antibody (Fig. 4b) . Conjugate 30 retained binding to HER2 (Fig. 4c) . Additionally, this experiment indicates that the Se-aryl linkage does not inhibit sortase A.
Our experiments highlight both the promises and challenges of using this chemistry for protein-small molecule conjugates. Although this methodology successfully yielded a homogeneous ADC that retained binding, the reaction itself was performed on a peptide and an additional sortase ligation was necessary to generate the final construct. In the future, our conjugation chemistry could be used in conjunction with techniques to site-specifically incorporate selenocysteine into large proteins, and so obviate the need for sortase ligation 30, 31 . However, selenocysteine incorporation into proteins has its own challenges, and the oxidation step to generate an electrophilic selenocysteine may affect other cysteine residues in the protein. Finally, it is critical that the small molecule retains activity at its electron-rich arene after substitution. As long as these parameters are considered in the molecular design of conjugates, we believe this chemistry is a powerful tool, especially in the cases of complex small molecules that are difficult to functionalize for conjugation.
Given that the use of complex small molecules is one of the most appealing aspects of this conjugation technique, we wanted to determine the breadth of the small-molecule substrate scope. This study began by investigating the reaction between molecules that possessed electron-rich arene groups and a model peptide that contained an activated selenocysteine (peptide 8, sequence NH 2 -GlySec*-Ala-Asn-Ser-Leu-Arg-Phe-Tyr-His-Asp-Lys-CONH 2 ; Sec* is the activated selenocysteine (Fig. 5) ). We found that arenes with two electron-donating substituents at the 1-and 3-positions are necessary for efficient conjugation (9a-9e). Phenol (9f) was unreactive under standard conditions, although some product was observed when CuSO 4 and a ligand (4,4′ -di-tert-butyl-2,2′ -dipyridyl (L1)) were added. Lastly, the reaction of 1,3,5-trimethoxybenzene (9g) with 8 yielded no desired conjugate. These results suggest that phenolic substrates are more reactive in their deprotonated forms.
Next, we surveyed nucleophilic heteroaromatic substrates (10a-10q (Fig. 5) ). Electron-rich five-membered heterocycles, such as indoles, pyrroles and aminoisoxazoles provided the respective conjugates in moderate-to-good yields, although the addition of CuSO 4 /L1 was sometimes needed to improve the overall efficiency of the conjugation (Supplementary Section 8) . Lastly, electron-rich six-membered heterocycles, such as 4-hydroxycoumarin (10m), 2,4-quinolinediol (10n) and 2,6-diaminopyridine (10o), were converted into the corresponding conjugates in good-to-excellent yields.
Having established the scope of the aromatic substrates that conjugate effectively to peptide 8, we turned our attention to complex small molecules (for example, natural products and pharmaceuticals) that have the intrinsic reactivity we imagined to be compatible with electrophilic selenocysteine-based conjugation. Natural products and pharmaceuticals with an embedded resorcinol ring, such as the β 2 -adrenoreceptor agonist 11a (fenoterol) 32 , dehydrogenase inhibitor 11c (gimeracil) 33 and the metabotropic glutamate receptor agonist 11e ((S)-3,5-dihydroxyphenylglycine) 34 , were all readily linked to peptide 8 in good-to-excellent yields. In general, these reactions were highly chemoselective, providing one regioisomer as indicated by NMR spectroscopy of the respective small moleculepeptide conjugate (Supplementary Section 10) . Additionally, 2-carbazolol (11g) and β -carboline harmol (11h) gave the corresponding conjugates in excellent yields, although a copper reagent was needed to improve the yield for the former. Phentolamine 35 , an antihypertensive drug (11i), also reacted efficiently. Lastly, indole-based Step 1 Native conjugation
Step 2 Sortagging molecules, such as pindolol (11j, a β -blocker) 36 and serotonin (11k, a neurotransmitter) 37 provided the corresponding products in high yields in the presence of the copper reagent.
In summary, we have described a reaction that enables the conjugation of peptides and proteins that contain a Sec to native, unfunctionalized small molecules. This strategy was demonstrated with over 30 different small molecules and 20 different polypeptide/protein sequences. We have done proof-of-concept experiments in two different areas of biological and clinical interest that show the utility of this conjugation strategy. First, we used our reaction to rapidly prepare conjugates between antimicrobial peptides and vancomycin. We screened our conjugates against several pathogens and identified those with activity against vancomycin-resistant Enterococcus and A. baumannii. Future research will focus on the role of both selenocysteine and vancomycin in the efficacy of the reported conjugates. However, our results suggest our conjugation chemistry may facilitate the design and discovery of new conjugates aimed at antibiotic-resistant infections. Second, we showed that for a small protein with a defined fold (affibody), our conjugation strategy does not disrupt the structure or binding affinity. We also utilized sortase ligation to generate an immunoglobulin-G antibody that contained the C-Se linkage to a small molecule and showed that the antibody retains its binding affinity. These experiments are a first step towards using this chemistry to create homogeneous ADCs. We envision combining this conjugation chemistry with techniques to incorporate selenocysteine into antibodies to give a one-step route to homogeneous ADCs. Given these results, we believe our chemistry will be a valuable bioconjugation technique for the community and may lead to the generation of therapeutic conjugate molecules.
Methods
Detailed experimental methods, synthetic procedures and characterization of the compounds are described in the Supplementary Information. 
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